Resubmission to FDA Planned for First Half of 2009 with Additional Data INDIANAPOLIS, Nov. 28 (HSMN NewsFeed) — Eli Lilly and Company (NYSE: LLY ) has withdrawn its supplemental New Drug Application (sNDA) from the U.S. Food and Drug Administration (…
Biopharmaceuticals
Eli Lilly, Cymbalta, duloxetine

If you are a sales professional or want to become one, or if you are looking for a new sales job, you will face one of the toughest interview processes of any job seeker.
0 Comments on “Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain”
Leave a Comment